trending Market Intelligence /marketintelligence/en/news-insights/trending/JaQbP_8UP8wH9MBs3_-53g2 content esgSubNav
In This List

Japan IP court rules in Lilly's favor on Alimta patents

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Japan IP court rules in Lilly's favor on Alimta patents

The Japan IP High Court ruled in favor of Eli Lilly & Co. in the invalidation trials initiated by Sawai Pharmaceutical Co. Ltd. regarding Lilly's vitamin regimen patents for Alimta.

The ruling has confirmed the decision of the Japanese Patent Office made in 2015, which upheld the validity of the Alimta vitamin regimen patents.

If the patents are upheld through all challenges, they could provide intellectual property protection for Alimta in Japan until June 2021. Lilly will take necessary actions to defend and enforce the patents.